2016-03-15T00:00:00.000-04:00
market cap,-0.727045
larger drugmakers,-0.311866
ReACT clinical trial,-0.714882
multiple solid tumors,0.289106
cancer immunotherapy atezolizumab,0.289106
bad news,-0.655735
study,5.61774E-4
clinical trials,-0.0489443
independent data safety,0.248162
cancer vaccine,-0.714882
future,-0.351935
Celldex executives,0.633479
Harsh reality,-0.493854
great expectations,0.540455
cancer. Bristol-Myers Squibb,0.289106
hard way,-0.243765
potentially seeing revenue,-0.413937
horrible Rintega news,-0.487871
Celldex,-0.136264
breast cancer,-0.582071
varli studies,-0.720639
clinical results,0.455029
disappointing news,-0.607752
drastic change,-0.773989
ACT IV data,0.497422
Previous phase,0.455029
company,-0.479757
clinical trial,-0.597319
good news,-0.0969157
varli/nivolumab study,0.623724
hope,0.497422
